學術發表 - OBI Pharma 台灣浩鼎

2024.Apr.11

Technology

Structure-Based High-Efficiency Homogeneous Antibody Platform by Endoglycosidase Sz Provides Insights into Its Transglycosylation Mechanism

2024.Apr.10

ADC

OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models

2024.Apr.10

ADC

OBI-992, a novel TROP2 targeting antibody drug conjugate demonstrates superior in vivo PK/PD properties and a favorable safety profile

2024.Apr.08

ADC

In vitro characterization of a novel TROP2-targeting antibody-drug conjugate OBI-992

2024.Apr.08

ADC

Development of a novel site-specific ADC glycan platform with potential for improved in vivo efficacy and stability of the ADC in animal studies

2023.Dec.19

Vaccine

Investigation of the impact of Globo-H expression on the progression of gastric cancer

2023.May.12

Prodrug

Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors

2023.Apr.04

Others

Globo H-Targeted CAR T Cell Cancer Immunotherapy

2023.Apr.04

ADC

OBI-999, an anti-Globo H antibody drug conjugate, exhibits synergistic anti-tumor effect in combination with pembrolizumab

2023.Mar.24

Vaccine

Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies